1. Home
  2. EXLS vs GRFS Comparison

EXLS vs GRFS Comparison

Compare EXLS & GRFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ExlService Holdings Inc.

EXLS

ExlService Holdings Inc.

HOLD

Current Price

$42.33

Market Cap

6.9B

ML Signal

HOLD

Logo Grifols S.A.

GRFS

Grifols S.A.

HOLD

Current Price

$9.19

Market Cap

6.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EXLS
GRFS
Founded
1999
1940
Country
United States
Spain
Employees
N/A
N/A
Industry
Business Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.9B
6.2B
IPO Year
2006
2006

Fundamental Metrics

Financial Performance
Metric
EXLS
GRFS
Price
$42.33
$9.19
Analyst Decision
Strong Buy
Hold
Analyst Count
4
2
Target Price
$54.50
$10.15
AVG Volume (30 Days)
1.2M
443.2K
Earning Date
02-24-2026
07-28-2022
Dividend Yield
N/A
1.53%
EPS Growth
29.94
N/A
EPS
1.48
0.64
Revenue
$2,026,490,000.00
$8,821,017,248.00
Revenue This Year
$15.32
$5.36
Revenue Next Year
$11.27
$5.15
P/E Ratio
$28.38
$18.34
Revenue Growth
14.43
7.31
52 Week Low
$37.30
$6.19
52 Week High
$52.43
$11.14

Technical Indicators

Market Signals
Indicator
EXLS
GRFS
Relative Strength Index (RSI) 55.06 55.13
Support Level $40.71 $9.04
Resistance Level $43.67 $9.46
Average True Range (ATR) 0.72 0.21
MACD -0.15 0.02
Stochastic Oscillator 51.04 64.10

Price Performance

Historical Comparison
EXLS
GRFS

About EXLS ExlService Holdings Inc.

ExlService Holdings Inc. is a business process management company that provides digital operations and analytical services to clients driving enterprise-scale business transformation initiatives that leverage the company's deep expertise in analytics, AI, ML, and cloud. The company offers business process outsourcing and automation services, and data-driven insights to customers across multiple industries. The company operates through four segments based on the products and services offered and markets served: Insurance, Healthcare, Emerging Business, and Analytics . The vast majority of the company's revenue is earned in the United States, and more than half of its revenue comes from Analytics segment.

About GRFS Grifols S.A.

Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.

Share on Social Networks: